National Policy on Traditional Medicine and Regulation of Herbal Medicines - Report of a WHO Global Survey
(2005; 168 pages) View the PDF document
Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
View the documentAcronyms, abbreviations and definitions
View the documentWHO Regions
Open this folder and view contents1. Introduction
Open this folder and view contents2. National policy on traditional medicine and complementary/alternative medicine
Close this folder3. The regulatory situation of herbal medicines
View the document3.1 Law or regulation on herbal medicines
View the document3.2 Regulatory status of herbal medicines
View the document3.3 Claims
View the document3.4 Pharmacopoeias
View the document3.5 Monographs on herbal medicines
View the document3.6 Manufacture of herbal medicines
View the document3.7 Safety and herbal medicines
View the document3.8 Registration system for herbal medicines
View the document3.9 Herbal medicines and the essential drug list
View the document3.10 Post marketing surveillance of herbal medicines
View the document3.11 The sale of herbal medicines
View the document3.12 Annual market sales of herbal medicines
Open this folder and view contents4. Member States, WHO and herbal medicines
Open this folder and view contents5. Country summaries
View the documentReferences
View the documentAnnex 1. Text of survey instrument
 

3.6 Manufacture of herbal medicines

Member States were next asked about regulatory requirements for the manufacture of herbal medicines. Possible answers included the following options: adherence to information in pharmacopoeias or monographs, the same GMP rules as for conventional pharmaceuticals, special GMP rules, no requirements and other requirements. Countries were able to choose all that applied. For clarification purposes, GMP was described as requirements in areas such as quality management, personnel, premises and equipment, documentation, production, quality control, contract manufacture and analysis, complaints and product recall and self inspection (13).

A total of 126 countries responded to this set of questions (see Figure 28). Most countries indicated that the same GMP rules as used for conventional pharmaceuticals were required for herbal medicines. The next largest number was reports of adherence to information in pharmacopoeias or monographs. Six countries provided additional regulatory requirements for manufacturing; these included the following: good hygienic practices, some elements of GMP (requirements about documentation, licensing of manufacture, packing, marking, design of pharmaceuticals), according to the United States Food and Drug Administration (FDA) regulations, and domestic and family practices.


Figure 28. Manufacturing: regulatory requirements

Member States were further asked whether the implementation of the regulatory requirements selected in the previous question was monitored by a control mechanism. If they answered affirmatively, the countries were asked to describe the type of control mechanism. Though 126 countries responded to this question, the figure below represents only the 101 countries that reported having some sort of regulatory requirements (i.e. excluding those countries which responded only “no requirements” or did not answer the previous question). As illustrated in Figure 29, 76%, or 77 countries, indicated that they have control mechanisms for manufacturing regulatory requirements.


Figure 29. Existence of control mechanisms for manufacturing requirements

Many responding countries provided details on the type of control mechanism used to ensure implementation of manufacturing regulatory requirements. Out of these, the most commonly cited control mechanisms were inspection and licensing of products or manufacturers.

to previous section to next section
 

Last updated: May 3, 2013